ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
On January10, 2017, ZIOPHARM Oncology, Inc., or the Company,
together with Intrexon Corporation, or Intrexon, issued a press
release announcing the signing of a Cooperative Research and
Development Agreement with the National Cancer Institute for the
development of adoptive cell transfer-based immunotherapies
genetically modified using the Sleeping Beauty
transposon/transposase system to express T-cell receptors for the
treatment of solid tumors.
A copy of the above referenced press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K. This
information, including the information contained in the press
release furnished as Exhibit 99.1, shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, and is not incorporated by reference into any of the
Companys filings, whether made before or after the date hereof,
regardless of any general incorporation language in any such
filing.
Item9.01 |
Financial Statements and Exhibits |
(d) |
Exhibits |
|
|
|
|
| 99.1 |
Press Release of the Company and Intrexon dated January 10, 2017 |
2
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Recent Trading Information
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed its last trading session up +0.08 at 5.83 with 1,850,637 shares trading hands.
